Last mentioned: Feb 21, 2026
Q4 2025 Earnings
Both companies report record performance and optimistic 2026 outlooks.
Payer Milestone
Talkspace surpasses 140 million covered lives through payer partnerships.
Talkspace Profitability
Talkspace achieves its first full quarter of adjusted EBITDA profitability.
Commercial Launch
Initial rollout of iDose TR begins in the U.S. market with targeted accounts.
iDose TR FDA Approval
Glaukos receives landmark approval for its travoprost intracameral implant.
N-able and Talkspace reported strong Q4 2025 results, highlighting a pivot toward high-margin recurring revenue and AI-driven efficiency. While N-able capitalizes on the growing MSP demand for cloud security, Talkspace demonstrates the scalability of B2B digital health platforms.
A flurry of Q4 2025 earnings reports reveals a bifurcated market where specialized medical technology and energy infrastructure are outperforming, while consumer discretionary and managed services face margin pressures. Glaukos Corporation and Targa Resources emerged as standout performers, signaling robust demand in high-barrier-to-entry sectors.
The Q4 2025 earnings cycle highlights a diverging cybersecurity landscape, with N-able reporting strong demand for managed security services while critical infrastructure and healthcare firms prioritize data privacy and OT protection. This briefing analyzes the intersection of security investment and operational resilience across five key market sectors.
Glaukos Corporation reported strong Q4 2025 results, driven by the rapid commercial adoption of its iDose TR sustained-release implant and a resilient MIGS franchise. The company's strategic shift toward dropless glaucoma therapies is yielding significant revenue growth and improved 2026 guidance.
Glaukos Corporation and Talkspace, Inc. reported strong Q4 2025 financial results, highlighting a successful transition toward high-margin, recurring revenue models. Glaukos saw significant gains from its iDose TR launch, while Talkspace solidified its position as a profitable, payer-led behavioral health leader.